Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2

Toshiyuki Yoneda, Akira Sasaki, Colin Dunstan, Paul J. Williams, Frieder Bauss, Yves A. De Clerck, Gregory R. Mundy

Research output: Contribution to journalArticle

222 Citations (Scopus)

Abstract

Multiple steps are involved in the metastasis of cancer cells from primary sites to distant organs. These steps should be considered in the design of pharmacologic approaches to prevent or inhibit the metastatic process. In the present study, we have compared the effects of inhibiting several steps involved in the bone metastatic process individually with inhibition of both together. The steps we chose were matrix metalloproteinase (MMP) secretion, likely involved in tumor cell invasion, and osteoclastic bone resorption, the final step in the process. We used an experimental model in which inoculation of human estrogen-independent breast cancer MDA-231 cells into the left cardiac ventricle of female nude mice causes osteolytic lesions in bone. To inhibit cancer invasiveness, the tissue inhibitor of the MMP-2 (TIMP-2), which is a natural inhibitor of MMPs, was over-expressed in MDA-231 cells. To inhibit bone resorption, a potent bisphosphonate, ibandronate (4 μg/mouse) was daily administered subcutaneously. Nude mice received either; (a) nontransfected MDA-231 cells; (b) nontransfected MDA- 231 cells and ibandronate; (c) TIMP-2-transfected MDA-231 cells; or (d) TIMP- 2-transfected MDA-231 cells and ibandronate. In mice from group a, radiographs revealed multiple osteolytic lesions. However, in mice from group b or group c, osteolytic lesions were markedly decreased. Of particular note, in animals from group d receiving both ibandronate and TIMP-2-transfected MDA-231 cells, there were no radiologically detectable osteolytic lesions. Survival rate was increased in mice of groups c and d. There was no difference in local enlargement in the mammary fat pad between nontransfected and TIMP-2-transfected MDA-231 cells. These results suggest that inhibition of both MMPs and osteoclastic bone resorption are more efficacious treatment for prevention of osleolytic lesions than either alone, and suggestthat when therapies are designed based on the uniqueness of the bone microenvironment and combined with several common steps in the metastatic process, osteolytic bone metastases can be more efficiently and selectively inhibited.

Original languageEnglish
Pages (from-to)2509-2517
Number of pages9
JournalJournal of Clinical Investigation
Volume99
Issue number10
Publication statusPublished - May 15 1997
Externally publishedYes

Fingerprint

Tissue Inhibitor of Metalloproteinase-2
Matrix Metalloproteinase 2
Diphosphonates
Breast Neoplasms
Neoplasm Metastasis
Bone and Bones
Matrix Metalloproteinase Inhibitors
Bone Resorption
Matrix Metalloproteinases
Nude Mice
Heart Ventricles
ibandronic acid
Neoplasms
Adipose Tissue
Estrogens
Breast
Theoretical Models

Keywords

  • bone metastasis
  • breast cancer
  • ibandronate
  • osteoclast
  • TIMP-2

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. / Yoneda, Toshiyuki; Sasaki, Akira; Dunstan, Colin; Williams, Paul J.; Bauss, Frieder; De Clerck, Yves A.; Mundy, Gregory R.

In: Journal of Clinical Investigation, Vol. 99, No. 10, 15.05.1997, p. 2509-2517.

Research output: Contribution to journalArticle

Yoneda, Toshiyuki ; Sasaki, Akira ; Dunstan, Colin ; Williams, Paul J. ; Bauss, Frieder ; De Clerck, Yves A. ; Mundy, Gregory R. / Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. In: Journal of Clinical Investigation. 1997 ; Vol. 99, No. 10. pp. 2509-2517.
@article{f3ddbd57ca6948b8bae28f5cf3ccef80,
title = "Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2",
abstract = "Multiple steps are involved in the metastasis of cancer cells from primary sites to distant organs. These steps should be considered in the design of pharmacologic approaches to prevent or inhibit the metastatic process. In the present study, we have compared the effects of inhibiting several steps involved in the bone metastatic process individually with inhibition of both together. The steps we chose were matrix metalloproteinase (MMP) secretion, likely involved in tumor cell invasion, and osteoclastic bone resorption, the final step in the process. We used an experimental model in which inoculation of human estrogen-independent breast cancer MDA-231 cells into the left cardiac ventricle of female nude mice causes osteolytic lesions in bone. To inhibit cancer invasiveness, the tissue inhibitor of the MMP-2 (TIMP-2), which is a natural inhibitor of MMPs, was over-expressed in MDA-231 cells. To inhibit bone resorption, a potent bisphosphonate, ibandronate (4 μg/mouse) was daily administered subcutaneously. Nude mice received either; (a) nontransfected MDA-231 cells; (b) nontransfected MDA- 231 cells and ibandronate; (c) TIMP-2-transfected MDA-231 cells; or (d) TIMP- 2-transfected MDA-231 cells and ibandronate. In mice from group a, radiographs revealed multiple osteolytic lesions. However, in mice from group b or group c, osteolytic lesions were markedly decreased. Of particular note, in animals from group d receiving both ibandronate and TIMP-2-transfected MDA-231 cells, there were no radiologically detectable osteolytic lesions. Survival rate was increased in mice of groups c and d. There was no difference in local enlargement in the mammary fat pad between nontransfected and TIMP-2-transfected MDA-231 cells. These results suggest that inhibition of both MMPs and osteoclastic bone resorption are more efficacious treatment for prevention of osleolytic lesions than either alone, and suggestthat when therapies are designed based on the uniqueness of the bone microenvironment and combined with several common steps in the metastatic process, osteolytic bone metastases can be more efficiently and selectively inhibited.",
keywords = "bone metastasis, breast cancer, ibandronate, osteoclast, TIMP-2",
author = "Toshiyuki Yoneda and Akira Sasaki and Colin Dunstan and Williams, {Paul J.} and Frieder Bauss and {De Clerck}, {Yves A.} and Mundy, {Gregory R.}",
year = "1997",
month = "5",
day = "15",
language = "English",
volume = "99",
pages = "2509--2517",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "10",

}

TY - JOUR

T1 - Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2

AU - Yoneda, Toshiyuki

AU - Sasaki, Akira

AU - Dunstan, Colin

AU - Williams, Paul J.

AU - Bauss, Frieder

AU - De Clerck, Yves A.

AU - Mundy, Gregory R.

PY - 1997/5/15

Y1 - 1997/5/15

N2 - Multiple steps are involved in the metastasis of cancer cells from primary sites to distant organs. These steps should be considered in the design of pharmacologic approaches to prevent or inhibit the metastatic process. In the present study, we have compared the effects of inhibiting several steps involved in the bone metastatic process individually with inhibition of both together. The steps we chose were matrix metalloproteinase (MMP) secretion, likely involved in tumor cell invasion, and osteoclastic bone resorption, the final step in the process. We used an experimental model in which inoculation of human estrogen-independent breast cancer MDA-231 cells into the left cardiac ventricle of female nude mice causes osteolytic lesions in bone. To inhibit cancer invasiveness, the tissue inhibitor of the MMP-2 (TIMP-2), which is a natural inhibitor of MMPs, was over-expressed in MDA-231 cells. To inhibit bone resorption, a potent bisphosphonate, ibandronate (4 μg/mouse) was daily administered subcutaneously. Nude mice received either; (a) nontransfected MDA-231 cells; (b) nontransfected MDA- 231 cells and ibandronate; (c) TIMP-2-transfected MDA-231 cells; or (d) TIMP- 2-transfected MDA-231 cells and ibandronate. In mice from group a, radiographs revealed multiple osteolytic lesions. However, in mice from group b or group c, osteolytic lesions were markedly decreased. Of particular note, in animals from group d receiving both ibandronate and TIMP-2-transfected MDA-231 cells, there were no radiologically detectable osteolytic lesions. Survival rate was increased in mice of groups c and d. There was no difference in local enlargement in the mammary fat pad between nontransfected and TIMP-2-transfected MDA-231 cells. These results suggest that inhibition of both MMPs and osteoclastic bone resorption are more efficacious treatment for prevention of osleolytic lesions than either alone, and suggestthat when therapies are designed based on the uniqueness of the bone microenvironment and combined with several common steps in the metastatic process, osteolytic bone metastases can be more efficiently and selectively inhibited.

AB - Multiple steps are involved in the metastasis of cancer cells from primary sites to distant organs. These steps should be considered in the design of pharmacologic approaches to prevent or inhibit the metastatic process. In the present study, we have compared the effects of inhibiting several steps involved in the bone metastatic process individually with inhibition of both together. The steps we chose were matrix metalloproteinase (MMP) secretion, likely involved in tumor cell invasion, and osteoclastic bone resorption, the final step in the process. We used an experimental model in which inoculation of human estrogen-independent breast cancer MDA-231 cells into the left cardiac ventricle of female nude mice causes osteolytic lesions in bone. To inhibit cancer invasiveness, the tissue inhibitor of the MMP-2 (TIMP-2), which is a natural inhibitor of MMPs, was over-expressed in MDA-231 cells. To inhibit bone resorption, a potent bisphosphonate, ibandronate (4 μg/mouse) was daily administered subcutaneously. Nude mice received either; (a) nontransfected MDA-231 cells; (b) nontransfected MDA- 231 cells and ibandronate; (c) TIMP-2-transfected MDA-231 cells; or (d) TIMP- 2-transfected MDA-231 cells and ibandronate. In mice from group a, radiographs revealed multiple osteolytic lesions. However, in mice from group b or group c, osteolytic lesions were markedly decreased. Of particular note, in animals from group d receiving both ibandronate and TIMP-2-transfected MDA-231 cells, there were no radiologically detectable osteolytic lesions. Survival rate was increased in mice of groups c and d. There was no difference in local enlargement in the mammary fat pad between nontransfected and TIMP-2-transfected MDA-231 cells. These results suggest that inhibition of both MMPs and osteoclastic bone resorption are more efficacious treatment for prevention of osleolytic lesions than either alone, and suggestthat when therapies are designed based on the uniqueness of the bone microenvironment and combined with several common steps in the metastatic process, osteolytic bone metastases can be more efficiently and selectively inhibited.

KW - bone metastasis

KW - breast cancer

KW - ibandronate

KW - osteoclast

KW - TIMP-2

UR - http://www.scopus.com/inward/record.url?scp=0030927205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030927205&partnerID=8YFLogxK

M3 - Article

VL - 99

SP - 2509

EP - 2517

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 10

ER -